Cypher AI has successfully secured $2 million in seed funding to advance its AI-native infrastructure aimed at revolutionizing life science research and development. The funding round was led by MaC Venture Capital, with contributions from several other investors, indicating strong market interest in innovative solutions for the biotech sector.
Founded in 2025 by Yaoyu Yang, Cypher AI aims to transform the current fragmented and outdated systems used in life science R&D. The company is developing a comprehensive platform that integrates experiment design, execution, analysis, and vendor management into a cohesive workflow. This initiative addresses the prevalent reliance on spreadsheets and disconnected documentation tools that hinder modern scientific processes.
Since its inception, Cypher AI has gained traction among biotechnology firms, with over 800 scientists reportedly utilizing the platform for more than 100,000 laboratory and computational workflows. The company's goal is to create a flexible infrastructure that adapts to evolving scientific needs, combining various essential tools like laboratory information management systems and electronic lab notebooks into a single, intelligent platform.
The newly acquired funding will facilitate the expansion of Cypher AI's platform, targeting biotech, pharmaceutical, and research organizations aiming to enhance their R&D capabilities. This shift towards an AI-native approach could significantly accelerate scientific discovery and innovation, positioning Cypher AI as a key player in the future of life sciences.